Government backs new AI health projects in the UK

UK government has backed five new centres for AI in health, which will be focusing on areas that includes pathology, radiology and imaging. Centres will be based in Leeds, Oxford, Coventry, Glasgow and London. Utilising £50m in funding, the new centres will bring together doctors, businesses and academics to collaborate on the development of products

Continue Reading

Clinical Professionals CEO, Yvette Cleland features on the Recruitment Rollercoaster Podcast

Yvette Cleland was recently interviewed by Hishem Azzouz for his Recruitment Rollercoaster podcast series. The series came about when Azzouz was searching for a recruitment related podcast to listen to on his work day commute. In particular something he could learn from that was still specific to the recruitment industry. During the podcast, “Yvette Cleland,

Continue Reading

Yvette Cleland Features in Recruitment International’s Meet the CEO!

Yvette Cleland, CEO of Clinical Professionals, spoke to Suhail Mirza about her career to date and the importance of training and development in recruitment. “In their summer 2018 Harvard Business Review Article (entitled “Manage Your Work, Manage Your Life”) academics, Boris Groysberg and Robin Abrahams state that in order to achieve the mythical work/life balance, leaders

Continue Reading

Positive results for AZ’s type 2 diabetes trial

AstraZeneca has reported positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) of BMS-512148 compared to placebo for the treatment of patients with type 2 diabetes (T2D). The trial had met its primary safety objective of non-inferiority for major adverse cardiovascular events (MACE). The trial also achieved one of its two

Continue Reading

Lilly commences plaque psoriasis treatment head to head trial

Eli Lilly and Company (Lilly) has commenced the IXORA-R head-to-head (H2H) clinical trial to investigate the efficacy and safety of ixekizumab when compared to guselkumab to treat adult patients with moderate-to-severe plaque psoriasis. Roughly 960 patients are expected to be included in the 24-week, multicentre, randomised, blinded, parallel-group trial. The trial’s primary objective is the

Continue Reading

Enrolment completed for phase 3 of Horizon’s Tyroid eye disease trial

Horizon Pharma has stated that their Phase III trial of teprotumumab in patients living with moderate-to-severe active thyroid eye disease (TED) has completed enrolment ahead of schedule. TED is a rare autoimmune disease where the insulin-like growth factor receptor (IGF-1R) is overexpressed on eye tissues, which then leads to local inflammation, orbital fibroblast proliferation and

Continue Reading